Organic nitrate therapy, nitrate tolerance, and nitrate-induced endothelial dysfunction: Emphasis on redox biology and oxidative stress

Antioxidants and Redox Signaling

Volumn 23, Issue 11, 2015, Pages 899-942

  Daiber, Andreas ^a   Münzel, Thomas ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 2; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIOXIDANT; CARVEDILOL; DIHYDROLIPOATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN RECEPTOR ANTAGONIST; GLUTATHIONE TRANSFERASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCERYL TRINITRATE; HEME OXYGENASE 1; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE 5 NITRATE; ISOSORBIDE DINITRATE; MICRORNA; ORGANIC NITRATE; PENTAERYTHRITYL TETRANITRATE; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIOL GROUP; THIOREDOXIN; TRANSCRIPTION FACTOR NRF2; XANTHINE OXIDASE; NITRIC ACID DERIVATIVE; REACTIVE OXYGEN METABOLITE; VASODILATOR AGENT;

ANTIOXIDANT ACTIVITY; BIOTRANSFORMATION; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DESENSITIZATION; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG CROSS TOLERANCE; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; ENZYME ACTIVITY; ENZYME MECHANISM; EPIGENETICS; GENE CONTROL; HEMODYNAMICS; HUMAN; ISCHEMIC PRECONDITIONING; LONG TERM CARE; NITRATION; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TACHYPHYLAXIS; TREATMENT RESPONSE; VASODILATATION; ANIMAL; CARDIOVASCULAR DISEASES; DRUG EFFECTS; METABOLISM; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; NITRATES; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; VASODILATOR AGENTS;

EID: 84944904699     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2015.6376     Document Type: Review

References (351)

1. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell infarto Miocardico. Lancet 343: 1115-1122, 1994
2. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 345: 669-685, 1995
3. Abou-Mohamed G, Johnson JA, Jin L, El-Remessy AB, Do K, Kaesemeyer WH, Caldwell RB, and Caldwell RW. Roles of superoxide, peroxynitrite, and protein kinase C in the development of tolerance to nitroglycerin. J Pharmacol Exp Ther 308: 289-299, 2004
4. Abrams J. A reappraisal of nitrate therapy. JAMA 259: 396-401, 1988
5. Abrams J. The role of nitrates in coronary heart disease. Arch Intern Med 155: 357-364, 1995
6. Ahlner J, Andersson RG, Axelsson KL, Bunnfors I, and Wallentin L. Effects of dipyridamole on the glyceryltrinitrate-induced inhibition of coronary artery muscle tone and platelet aggregation in relation to cyclic nucleotide metabolism. Acta Pharmacol Toxicol (Copenh) 57: 88-95, 1985
7. Aktories K, Forth W, and Allgaier C. Allgemeine und spezielle Pharmakologie und Toxikologie: für Studenten Der Medizin, Veterinarmedizin, Pharmazie, Chemie und Biologie sowie für A rzte, Tierarzte und Apotheker; mit 305 Tabellen. München: Elsevier, Urban & Fischer, 2009, vol. XXIV, p. 1224
8. Altenhofer S, Radermacher KA, Kleikers PW, Wingler K, and Schmidt HH. Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement. Antioxid Redox Signal 23: 406-427, 2015
9. Ambrosio G, Del Pinto M, Tritto I, Agnelli G, Bentivoglio M, Zuchi C, Anderson FA, Gore JM, Lopez-Sendon J, Wyman A, Kennelly BM, and Fox KA. Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52,693 patients in the Global Registry of Acute Coronary Events. Eur Heart J 31: 430-438, 2010
10. Artinian L, Zhong L, Yang H, and Rehder V. Nitric oxide as intracellular modulator: internal production of NO increases neuronal excitability via modulation of several ionic conductances. Eur J Neurosci 36: 3333-3343, 2012
11. Asbrink S, Zickert A, Bratt J, Gyllenhammar H, and Palmblad J. No effect of carvedilol on nitric oxide generation in phagocytes but modulation of production of superoxide ions. Biochem Pharmacol 59: 1007-1013, 2000
12. Axelsson KL and Karlsson JO. Nitroglycerin tolerance in vitro: effect on cGMP turnover in vascular smoothmuscle. Acta Pharmacol Toxicol (Copenh) 55: 203-210, 1984
13. Azevedo ER, Schofield AM, Kelly S, and Parker JD. Nitroglycerin withdrawal increases endothelium-dependent vasomotor response to acetylcholine. J Am Coll Cardiol 37: 505-509, 2001
14. Bachschmid M, Schildknecht S, and Ullrich V. Redox regulation of vascular prostanoid synthesis by the nitric oxide-superoxide system. Biochem Biophys Res Commun 338: 536-542, 2005
15. Bassenge E, Fink N, Skatchkov M, and Fink B. Dietary supplement with vitamin C prevents nitrate tolerance. J Clin Invest 102: 67-71, 1998
16. Bennett BM, Kobus SM, Brien JF, Nakatsu K, andMarks GS. Requirement for reduced, unliganded hemoprotein for the hemoglobin- and myoglobin-mediated biotransformation of glyceryl trinitrate. J Pharmacol Exp Ther 237: 629-635, 1986
17. Bennett BM, McDonald BJ, and St James MJ. Hepatic cytochrome P-450-mediated activation of rat aortic guanylyl cyclase by glyceryl trinitrate. J Pharmacol Exp Ther 261: 716-723, 1992
18. Beretta M, Gorren AC, Wenzl MV, Weis R, Russwurm M, Koesling D, Schmidt K, and Mayer B. Characterization of the East Asian variant of aldehyde dehydrogenase-2: bioactivation of nitroglycerin and effects of Alda-1. J Biol Chem 285: 943-952, 2010
19. Beretta M, Gruber K, Kollau A, Russwurm M, Koesling D, Goessler W, Keung WM, Schmidt K, and Mayer B. Bioactivation of nitroglycerin by purified mitochondrial and cytosolic aldehyde dehydrogenases. J Biol Chem 283: 17873-17880, 2008
20. Beretta M, Sottler A, Schmidt K, Mayer B, and Gorren AC. Partially irreversible inactivation of mitochondrial aldehyde dehydrogenase by nitroglycerin. J Biol Chem 283: 30735-30744, 2008
21. Beretta M, Wolkart G, Schernthaner M, Griesberger M, Neubauer R, Schmidt K, SachererM, Heinzel FR, Kohlwein SD, and Mayer B. Vascular bioactivation of nitroglycerin is catalyzed by cytosolic aldehyde dehydrogenase-2. Circ Res 110: 385-393, 2012
22. Berkenboom G, Fontaine D, Unger P, Baldassarre S, Preumont N, and Fontaine J. Absence of nitrate tolerance after long-term treatment with ramipril: an endothelium-dependent mechanism. J Cardiovasc Pharmacol 34: 547-553, 1999
23. Boesgaard S, Aldershvile J, and Poulsen HE. Preventive administration of intravenous N-acetylcysteine and development of tolerance to isosorbide dinitrate in patients with angina pectoris. Circulation 85: 143-149, 1992
24. Booth BP, Jacob S, Bauer JA, and Fung HL. Sustained antiplatelet properties of nitroglycerin during hemodynamic tolerance in rats. J Cardiovasc Pharmacol 28: 432-438, 1996
25. Brandes RP. Triggeringmitochondrial radical release: a new function for NADPH oxidases. Hypertension 45: 847-848, 2005
26. Brandes RP, Weissmann N, and Schroder K. Nox family NADPH oxidases: molecular mechanisms of activation. Free Radic Biol Med 76: 208-226, 2014
27. Brune B, Schmidt KU, and Ullrich V. Activation of soluble guanylate cyclase by carbon monoxide and inhibition by superoxide anion. Eur J Biochem 192: 683-688, 1990
28. Brunton TL. The action of nitrate of amyl on the circulation. J Anat Physiol 5: 92-101, 1870
29. Bryan NS, Calvert JW, Elrod JW, Gundewar S, Ji SY, and Lefer DJ. Dietary nitrite supplementation protects against myocardial ischemia-reperfusion injury. Proc Natl Acad Sci U S A 104: 19144-19149, 2007
30. Buccellati C, Sala A, Rossoni G, Capra V, Rovati GE, Di Gennaro A, Folco G, Colli S, and Casagrande C. Pharmacological characterization of 2NTX-99 [4-methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinylmethyl)-1,3-benz enedicarboxamide], a potential antiatherothrombotic agent with antithromboxane and nitric oxide donor activity in platelet and vascular preparations. J Pharmacol Exp Ther 317: 830-837, 2006
31. Budas GR, Disatnik MH, and Mochly-Rosen D. Aldehyde dehydrogenase 2 in cardiac protection: a new therapeutic target? Trends Cardiovasc Med 19: 158-164, 2009
32. Butler AR and Feelisch M. Therapeutic uses of inorganic nitrite and nitrate: from the past to the future. Circulation 117: 2151-2159, 2008
33. Cai H, Griendling KK, and Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 24: 471-478, 2003
34. Caramori PR, Adelman AG, Azevedo ER, Newton GE, Parker AB, and Parker JD. Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine. J Am Coll Cardiol 32: 1969-1974, 1998
35. Chen CA, De Pascali F, Basye A, Hemann C, and Zweier JL. Redox modulation of endothelial nitric oxide synthase by glutaredoxin-1 through reversible oxidative post-translational modification. Biochemistry 52: 6712-6723, 2013
36. Chen CA, Wang TY, Varadharaj S, Reyes LA, Hemann C, Talukder MA, Chen YR, Druhan LJ, and Zweier JL. Sglutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 468: 1115-1118, 2010
37. Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, and Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 321: 1493-1495, 2008
38. Chen K and Keaney JF Jr. Evolving concepts of oxidative stress and reactive oxygen species in cardiovascular disease. Curr Atheroscler Rep 14: 476-483, 2012
39. Chen Z, Foster MW, Zhang J, Mao L, Rockman HA, Kawamoto T, Kitagawa K, Nakayama KI, Hess DT, and Stamler JS. An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation. Proc Natl Acad Sci U S A 102: 12159-12164, 2005
40. Chen Z and Stamler JS. Bioactivation of nitroglycerin by the mitochondrial aldehyde dehydrogenase. Trends Cardiovasc Med 16: 259-265, 2006
41. Chen Z, Zhang J, and Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A 99: 8306-8311, 2002
42. Chirkov YY, Holmes AS, Chirkova LP, and Horowitz JD. Nitrate resistance in platelets from patients with stable angina pectoris. Circulation 100: 129-134, 1999
43. ChirkovYY,HolmesAS,Willoughby SR, Stewart S,Wuttke RD, Sage PR, and Horowitz JD. Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets. J Am Coll Cardiol 37: 1851-1857, 2001
44. Chowdhury MA, Abdellatif KR, Dong Y, Yu G, Huang Z, Rahman M, Das D, Velazquez CA, Suresh MR, and Knaus EE. Celecoxib analogs possessing a N-(4-nitrooxybutyl)piperidin-4-yl or N-(4-nitrooxybutyl)-1,2,3,6-tetrahydropyridin-4-yl nitric oxide donor moiety: synthesis, biological evaluation and nitric oxide release studies. Bioorg Med Chem Lett 20: 1324-1329, 2010
45. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, FrancisGS, Flohr KH, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 314: 1547-1552, 1986
46. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, et al. A comparison of enalapril with hydralazineisosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325: 303-310, 1991
47. Colussi C, Scopece A, Vitale S, Spallotta F, Mattiussi S, Rosati J, Illi B, Mai A, Castellano S, Sbardella G, Farsetti A, Capogrossi MC, and Gaetano C. P300/CBP associated factor regulates nitroglycerin-dependent arterial relaxation by N{varepsilon}-lysine acetylation of contractile proteins. Arterioscler Thromb Vasc Biol 32: 2435-2443, 2012
48. Contractor H, Stottrup NB, Cunnington C, Manlhiot C, Diesch J, Ormerod JO, Jensen R, Botker HE, Redington A, Schmidt MR, Ashrafian H, and Kharbanda RK. Aldehyde dehydrogenase-2 inhibition blocks remote preconditioning in experimental and human models. Basic Res Cardiol 108: 343, 2013
49. Cooper MP and Keaney JF Jr. Epigenetic control of angiogenesis via DNA methylation. Circulation 123: 2916-2918, 2011
50. Crabtree MJ, Brixey R, Batchelor H, Hale AB, and Channon KM. Integrated redox sensor and effector functions for tetrahydrobiopterin- and glutathionylationdependent endothelial nitric-oxide synthase uncoupling. J Biol Chem 288: 561-569, 2013
51. Crassous PA, Couloubaly S, Huang C, Zhou Z, Baskaran P, KimDD, PapapetropoulosA, FioramontiX,DuranWN, and Beuve A. Soluble guanylyl cyclase is a target of angiotensin II-induced nitrosative stress in a hypertensive rat model. Am J Physiol Heart Circ Physiol 303: H597-H604, 2012
52. Crisafulli A,Melis F, Tocco F, Santoboni UM, Lai C, Angioy G, Lorrai L, Pittau G, Concu A, and Pagliaro P. Exerciseinduced and nitroglycerin-induced myocardial preconditioning improves hemodynamics in patients with angina. Am J Physiol Heart Circ Physiol 287: H235-H242, 2004
53. Crow JP and Beckman JS. Reaction between nitric oxide, superoxide, and peroxynitrite: footprints of peroxynitrite in vivo. Adv Pharmacol 35: 17-43, 1995
54. Dsouza Y, Dowlatshahi S, and Bennett BM. Changes in aldehyde dehydrogenase 2 expression in rat blood vessels during glyceryl trinitrate tolerance development and reversal. Br J Pharmacol 164: 632-643, 2011
55. Daiber A. Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species. Biochim Biophys Acta 1797: 897-906, 2010
56. Daiber A, August M, Baldus S, Wendt M, Oelze M, Sydow K, Kleschyov AL, and Munzel T. Measurement of NAD(P)H oxidase-derived superoxide with the luminol analogue L-012. Free Radic Biol Med 36: 101-111, 2004
57. DaiberAand Munzel T. Characterization of the antioxidant properties of pentaerithrityl tetranitrate (PETN)-induction of the intrinsic antioxidative system heme oxygenase-1 (HO-1). Methods Mol Biol 594: 311-326, 2010
58. Daiber A and Munzel T. Nitrate reductase activity of mitochondrial aldehyde dehydrogenase (ALDH-2) as a redox sensor for cardiovascular oxidative stress. Methods Mol Biol 594: 43-55, 2010
59. Daiber A, Munzel T, and Gori T. Organic nitrates and nitrate tolerance-state of the art and future developments. Adv Pharmacol 60: 177-227, 2010
60. Daiber A, Oelze M, August M, Wendt M, Sydow K, Wieboldt H, Kleschyov AL, and Munzel T. Detection of super-oxide and peroxynitrite in model systems and mitochondria by the luminol analogue L-012. Free Radic Res 38: 259-269, 2004
61. Daiber A, Oelze M, Coldewey M, Bachschmid M, Wenzel P, Sydow K, Wendt M, Kleschyov AL, Stalleicken D, Ullrich V, Mulsch A, and Munzel T. Oxidative stress and mitochondrial aldehyde dehydrogenase activity: a comparison of pentaerythritol tetranitrate with other organic nitrates. Mol Pharmacol 66: 1372-1382, 2004
62. Daiber A, Oelze M, Coldewey M, Kaiser K, Huth C, Schildknecht S, Bachschmid M, Nazirisadeh Y, Ullrich V, Mulsch A, Munzel T, and Tsilimingas N. Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem Biophys Res Commun 338: 1865-1874, 2005
63. Daiber A, Oelze M, Daub S, Steven S, Schuff A, Kroller-Schon S, Hausding M, Wenzel P, Schulz E, Gori T, and Munzel T. Vascular redox signaling, redox switches in endothelial nitric oxide synthase and endothelial dysfunction. In: Systems Biology of Free Radicals and Antioxidants, edited by Laher I. Berlin Heidelberg: Springer-Verlag, 2014, pp. 1177-1211
64. Daiber A, Oelze M, Sulyok S, Coldewey M, Schulz E, TreiberN,HinkU,Mulsch A, Scharffetter-Kochanek K, and Munzel T. Heterozygous deficiency of manganese superoxide dismutase in mice (Mn-SOD+/-): a novel approach to assess the role of oxidative stress for the development of nitrate tolerance. Mol Pharmacol 68: 579-588, 2005
65. Daiber A, Oelze M, Wenzel P, Bollmann F, Pautz A, and Kleinert H. Heme oxygenase-1 induction and organic nitrate therapy: beneficial effects on endothelial dysfunction, nitrate tolerance, and vascular oxidative stress. Int J Hypertens 2012: 842632, 2012
66. Daiber A, Oelze M, Wenzel P, Wickramanayake JM, Schuhmacher S, Jansen T, Lackner KJ, Torzewski M, and Munzel T. Nitrate tolerance as a model of vascular dysfunction: roles for mitochondrial aldehyde dehydrogenase and mitochondrial oxidative stress. Pharmacol Rep 61: 33-48, 2009
67. Daiber A,Wenzel P, Oelze M, and Munzel T. New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance. Clin Res Cardiol 97: 12-20, 2008
68. This reference has been deleted
69. Daiber A, Wenzel P, Oelze M, Schuhmacher S, Jansen T, and Munzel T. Mitochondrial aldehyde dehydrogenase (ALDH-2)-maker of and marker for nitrate tolerance in response to nitroglycerin treatment. Chem Biol Interact 178: 40-47, 2009
70. De Garavilla L, Pagani ED, Buchholz RA, Dundore R, Bode DC, Volberg ML, Jackson KN, Pratt P, and Silver PJ. Zaprinast, but not dipyridamole, reverses hemodynamic tolerance to nitroglycerin in vivo. Eur J Pharmacol 313: 89-96, 1996
71. De Pascali F, Hemann C, Samons K, Chen CA, and Zweier JL. Hypoxia and reoxygenation induce endothelial nitric oxide synthase uncoupling in endothelial cells through tetrahydrobiopterin depletion and S-glutathionylation. Biochemistry 53: 3679-3688, 2014
72. Dezfulian C, Raat N, Shiva S, and Gladwin MT. Role of the anion nitrite in ischemia-reperfusion cytoprotection and therapeutics. Cardiovasc Res 75: 327-338, 2007
73. DiFabio JM, Thomas GR, Zucco L, Kuliszewski MA, Bennett BM, Kutryk MJ, and Parker JD. Nitroglycerin attenuates human endothelial progenitor cell differentiation, function, and survival. J Pharmacol Exp Ther 318: 117-123, 2006
74. Dikalov SI, Nazarewicz RR, Bikineyeva A, Hilenski L, LassegueB, GriendlingKK,HarrisonDG, andDikalovaAE. Nox2-induced production of mitochondrial superoxide in angiotensin II-mediated endothelial oxidative stress and hypertension. Antioxid Redox Signal 20: 281-294, 2014
75. Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, Lewis W, Harrison DG, and Dikalov SI. Therapeutic targeting of mitochondrial superoxide in hypertension. Circ Res 107: 106-116, 2010
76. Doel JJ, Godber BL, Eisenthal R, and Harrison R. Reduction of organic nitrates catalysed by xanthine oxidoreductase under anaerobic conditions. Biochim Biophys Acta 1527: 81-87, 2001
77. Doughan AK, Harrison DG, and Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res 102: 488-496, 2008
78. Dovinova I, Cacanyiova S, Faberova V, and Kristek F. The effect of an NO donor, pentaerythrityl tetranitrate, on biochemical, functional, and morphological attributes of cardiovascular system of spontaneously hypertensive rats. Gen Physiol Biophys 28: 86-93, 2009
79. Dragoni S, Gori T, Lisi M, Di Stolfo G, Pautz A, Kleinert H, and Parker JD. Pentaerythrityl tetranitrate and nitroglycerin, but not isosorbide mononitrate, prevent endothelial dysfunction induced by ischemia and reperfusion. Arterioscler Thromb Vasc Biol 27: 1955-1959, 2007
80. Dudek M, Bednarski M, Bilska A, Iciek M, Sokolowska-Jezewicz M, Filipek B, and Wlodek L. The role of lipoic acid in prevention of nitroglycerin tolerance. Eur J Pharmacol 591: 203-210, 2008
81. Elkayam U, Kulick D, McIntosh N, Roth A, Hsueh W, and Rahimtoola SH. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation 76: 577-584, 1987
82. Elkayam U, Roth A, Mehra A, Ostrzega E, Shotan A, Kulick D, Jamison M, Johnston JV, and Rahimtoola SH. Randomized study to evaluate the relation between oral isosorbide dinitrate dosing interval and the development of early tolerance to its effect on left ventricular filling pressure in patients with chronic heart failure. Circulation 84: 2040-2048, 1991
83. Esplugues JV, Rocha M, Nunez C, Bosca I, Ibiza S, Herance JR, Ortega A, Serrador JM, D'Ocon P, and Victor VM. Complex I dysfunction and tolerance to nitroglycerin: an approach based on mitochondrial-targeted antioxidants. Circ Res 99: 1067-1075, 2006
84. Fang L, Appenroth D, Decker M, Kiehntopf M, Roegler C, Deufel T, Fleck C, Peng S, Zhang Y, and Lehmann J. Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates. J Med Chem 51: 713-716, 2008
85. Feelisch M, Noack E, and Schroder H. Explanation of the discrepancy between the degree of organic nitrate decomposition, nitrite formation and guanylate cyclase stimulation. Eur Heart J 9 Suppl A: 57-62, 1988
86. Fernhoff NB, Derbyshire ER, Underbakke ES, and Marletta MA. Heme-assisted S-nitrosation desensitizes ferric soluble guanylate cyclase to nitric oxide. J Biol Chem 287: 43053-43062, 2012
87. Fink B and Bassenge E. Association between vascular tolerance and platelet upregulation: comparison of nonintermittent administration of pentaerithrityltetranitrate and glyceryltrinitrate. J Cardiovasc Pharmacol 40: 890-897, 2002
88. Fink B, Schwemmer M, Fink N, and Bassenge E. Tolerance to nitrates with enhanced radical formation suppressed by carvedilol. J Cardiovasc Pharmacol 34: 800-805, 1999
89. Fino V. Ascanio Sobrero. Torino 8: 6-24, 1889
90. Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, and Busse R. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res 88: E68-E75, 2001
91. Florczyk UM, Jozkowicz A, and Dulak J. Biliverdin reductase: new features of an old enzyme and its potential therapeutic significance. Pharmacol Rep 60: 38-48, 2008
92. Fontaine D, Otto A, Fontaine J, and Berkenboom G. Prevention of nitrate tolerance by long-term treatment with statins. Cardiovasc Drugs Ther 17: 123-128, 2003
93. Frame MD, Fox RJ, Kim D, Mohan A, Berk BC, and Yan C. Diminished arteriolar responses in nitrate tolerance involve ROS and angiotensin II. Am J Physiol Heart Circ Physiol 282: H2377-H2385, 2002
94. Freedman SB, Daxini BV, Noyce D, and Kelly DT. Intermittent transdermal nitrates do not improve ischemia in patients taking beta-blockers or calcium antagonists: potential role of rebound ischemia during the nitrate-free period. J Am Coll Cardiol 25: 349-355, 1995
95. Fritz KS, Galligan JJ, Smathers RL, Roede JR, Shearn CT, Reigan P, and Petersen DR. 4-Hydroxynonenal inhibits SIRT3 via thiol-specific modification. Chem Res Toxicol 24: 651-662, 2011
96. Fukatsu A, Hayashi T, Miyazaki-Akita A, Matsui-Hirai H, Furutate Y, Ishitsuka A, Hattori Y, and Iguchi A. Possible usefulness of apocynin, an NADPH oxidase inhibitor, for nitrate tolerance: prevention of NO donor-induced endothelial cell abnormalities. Am J Physiol Heart Circ Physiol 293: H790-H797, 2007
97. Fukuda S, Sakuma K, Tsukui A, Fujiwara N, Tanaka T, Fujihara H, Toriumi T, and Shimoji K. Hypoxia modifies the vasodilatory effects of nitroglycerin, prostaglandin E1, and hydralazine on isolated porcine coronary arteries. J Cardiovasc Pharmacol 23: 852-858, 1994
98. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Q 4th, Taylor WR, Harrison DG, De Leon H, Wilcox JN, and Griendling KK. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 80: 45-51, 1997
99. Fung HL. Biochemical mechanism of nitroglycerin action and tolerance: is this old mystery solved? Annu Rev Pharmacol Toxicol 44: 67-85, 2004
100. Fung HL, Chung SJ, Bauer JA, Chong S, and Kowaluk EA. Biochemical mechanism of organic nitrate action. Am J Cardiol 70: 4B-10B, 1992
101. Fung HL, Chung SJ, Chong S, Hough K, Kakami M, and Kowaluk E. Cellular mechanisms of nitrate action. Z Kardiol 78 Suppl 2: 14-17; discussion 64-67, 1989
102. Galougahi KK, Liu CC, Gentile C, Kok C, Nunez A, Garcia A, Fry NA, Davies MJ, Hawkins CL, Rasmussen HH, and Figtree GA. Glutathionylation mediates angiotensin II-induced eNOS uncoupling, amplifying NADPH oxidase-dependent endothelial dysfunction. J Am Heart Assoc 3: e000731, 2014
103. Garcia-Bou R, Rocha M, Apostolova N, Herance R, Hernandez-Mijares A, and Victor VM. Evidence for a relationship between mitochondrial Complex I activity and mitochondrial aldehyde dehydrogenase during nitroglycerin tolerance: effects of mitochondrial antioxidants. Biochim Biophys Acta 1817: 828-837, 2012
104. Garcia JI, Seabra AB, Kennedy R, and English AM. Nitrite and nitroglycerin induce rapid release of the vasodilator ATP from erythrocytes: relevance to the chemical physiology of local vasodilation. J Inorg Biochem 104: 289-296, 2010
105. Ge W, Guo R, and Ren J. AMP-dependent kinase and autophagic flux are involved in aldehyde dehydrogenase-2-induced protection against cardiac toxicity of ethanol. Free Radic Biol Med 51: 1736-1748, 2011
106. Ghio S, De Servi S, Perotti R, Eleuteri E, Montemartini C, and Specchia G. Different susceptibility to the development of nitroglycerin tolerance in the arterial and venous circulation in humans. Effects of N-acetylcysteine administration. Circulation 86: 798-802, 1992
107. Gladwin MT, Schechter AN, Kim-Shapiro DB, Patel RP, Hogg N, Shiva S,CannonRO3rd,KelmM,WinkDA, Espey MG, Oldfield EH, Pluta RM, Freeman BA, Lancaster JR Jr., Feelisch M, and Lundberg JO. The emerging biology of the nitrite anion. Nat Chem Biol 1: 308-314, 2005
108. Gomes KM, Campos JC, Bechara LR, Queliconi B, Lima VM, Disatnik MH, Magno P, Chen CH, Brum PC, Kowaltowski AJ, Mochly-Rosen D, and Ferreira JC. Aldehyde dehydrogenase 2 activation in heart failure restores mitochondrial function and improves ventricular function and remodelling. Cardiovasc Res 103: 498-508, 2014
109. Gori T, Burstein JM, Ahmed S, Miner SE, Al-Hesayen A, Kelly S, and Parker JD. Folic acid prevents nitroglycerininduced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation 104: 1119-1123, 2001
110. Gori T and Daiber A. Non-hemodynamic effects of organic nitrates and the distinctive characteristics of pentaerithrityl tetranitrate. Am J Cardiovasc Drugs 9: 7-15, 2009
111. Gori T, Fineschi M, Parker JD, and Forconi S. Current perspectives. Therapy with organic nitrates: newer ideas, more controversies. Ital Heart J 6: 541-548, 2005
112. Gori T, Floras JS, and Parker JD. Effects of nitroglycerin treatment on baroreflex sensitivity and short-term heart rate variability in humans. J Am Coll Cardiol 40: 2000-2005, 2002
113. Gori T and Forconi S. The role of reactive free radicals in ischemic preconditioning-clinical and evolutionary implications. Clin Hemorheol Microcirc 33: 19-28, 2005
114. Gori T, Harvey P, Floras JS, and Parker JD. Continuous therapy with nitroglycerin impairs endothelium-dependent vasodilation but does not cause tolerance in conductance arteries: a human in vivo study. J Cardiovasc Pharmacol 44: 601-606, 2004
115. Gori T, Mak SS, Kelly S, and Parker JD. Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans. J Am Coll Cardiol 38: 1096-1101, 2001
116. Gori T, Saunders L, Ahmed S, and Parker JD. Effect of folic acid on nitrate tolerance in healthy volunteers: differences between arterial and venous circulation. J Cardiovasc Pharmacol 41: 185-190, 2003
117. Gorren AC, Russwurm M, Kollau A, Koesling D, Schmidt K, and Mayer B. Effects of nitroglycerin/L-cysteine on soluble guanylate cyclase: evidence for an activation/inactivation equilibrium controlled by nitric oxide binding and haem oxidation. Biochem J 390: 625-631, 2005
118. Greenacre SA and Ischiropoulos H. Tyrosine nitration: localisation, quantification, consequences for protein function and signal transduction. Free Radic Res 34: 541-581, 2001
119. Gresele P and Momi S. Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Cardiovasc Drug Rev 24: 148-168, 2006
120. Griendling KK, Sorescu D, and Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86: 494-501, 2000
121. Griesberger M, Kollau A, Wolkart G, Wenzl MV, Beretta M, Russwurm M, Koesling D, Schmidt K, Gorren AC, and Mayer B. Bioactivation of pentaerythrityl tetranitrate by mitochondrial aldehyde dehydrogenase. Mol Pharmacol 79: 541-548, 2011
122. Gruhn N, Aldershvile J, and Boesgaard S. Tetrahydrobiopterin improves endothelium-dependent vasodilation in nitroglycerin-tolerant rats. Eur J Pharmacol 416: 245-249, 2001
123. Guo Y, Yu W, Sun D, Wang J, Li C, Zhang R, Babcock SA, Li Y, Liu M, Ma M, Shen M, Zeng C, Li N, He W, Zou Q, Zhang Y, and Wang H. A novel protective mechanism for mitochondrial aldehyde dehydrogenase (ALDH2) in type I diabetes-induced cardiac dysfunction: role of AMPK-regulated autophagy. Biochim Biophys Acta 1852: 319-331, 2015
124. Hacker A, Muller S, Meyer W, and Kojda G. The nitric oxide donor pentaerythritol tetranitrate can preserve endothelial function in established atherosclerosis. Br J Pharmacol 132: 1707-1714, 2001
125. Hagos GK, Abdul-Hay SO, Sohn J, Edirisinghe PD, Chandrasena RE, Wang Z, Li Q, and Thatcher GR. Antiinflammatory, antiproliferative, and cytoprotective activity of NO chimera nitrates of use in cancer chemoprevention. Mol Pharmacol 74: 1381-1391, 2008
126. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, PetrieMC, Sonntag F, UvaMS, Storey RF,WijnsW, Zahger D; ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for themanagement of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32: 2999-3054, 2011
127. Hare JM. Nitroso-redox balance in the cardiovascular system. N Engl J Med 351: 2112-2114, 2004
128. Harraz OF, Brett SE, and Welsh DG. Nitric oxide suppresses vascular voltage-gated T-type Ca2+ channels through cGMP/PKG signaling. Am J Physiol Heart Circ Physiol 306: H279-H285, 2014
129. Hausenloy D, Wynne A, Duchen M, and Yellon D. Transient mitochondrial permeability transition pore opening mediates preconditioning-induced protection. Circulation 109: 1714-1717, 2004
130. Haustein KO, Winkler U, Loffler A, and Huller G. Absorption and bioavailability of pentaerithrityl-tetranitrate (PETN, Dilcoran 80). Int J Clin Pharmacol Ther 33: 95-102, 1995
131. Hebert D and Lam JY. Nitroglycerin rebound associated with vascular, rather than platelet, hypersensitivity. J Am Coll Cardiol 36: 2311-2316, 2000
132. Heitzer T, Just H, Brockhoff C, Meinertz T, Olschewski M, and Münzel T. Long-term nitroglycerin treatment is associated with supersensitivity to vasoconstrictors in men with stable coronary artery disease: prevention by concomitant treatment with captopril. J Am Coll Cardiol 31: 83-88, 1998
133. Heitzer T, Just H, Brockhoff C, Meinertz T, Olschewski M, and Münzel T. Long-term nitroglycerin treatment is associated with supersensitivity to vasoconstrictors in men with stable coronary artery disease: prevention by concomitant treatment with captopril. J Am Coll Cardiol 31: 83-88, 1998
134. Hematian S, Siegler MA, and Karlin KD. Heme/copper assembly mediated nitrite and nitric oxide interconversion. J Am Chem Soc 134: 18912-18915, 2012
135. Hematian S, Siegler MA, and Karlin KD. Nitric oxide generation from heme/copper assembly mediated nitrite reductase activity. J Biol Inorg Chem 19: 515-528, 2014
136. Hink U, Daiber A, Kayhan N, Trischler J, Kraatz C, OelzeM, Mollnau H, Wenzel P, Vahl CF, Ho KK, Weiner H, and Munzel T. Oxidative inhibition of themitochondrial aldehyde dehydrogenase promotes nitroglycerin tolerance in human blood vessels. J Am Coll Cardiol 50: 2226-2232, 2007
137. Hink U, Oelze M, Kolb P, Bachschmid M, Zou MH, Daiber A, Mollnau H, August M, Baldus S, Tsilimingas N, Walter U, Ullrich V, and Munzel T. Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. J Am Coll Cardiol 42: 1826-1834, 2003
138. HolmesAS,ChirkovYY,Willoughby SR, Poropat S, Pereira J, and Horowitz JD. Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance. Br J Clin Pharmacol 60: 355-363, 2005
139. Huellner MW, Schrepfer S, Weyand M, Weiner H, Wimplinger I, Eschenhagen T, and Rau T. Inhibition of aldehyde dehydrogenase type 2 attenuates vasodilatory action of nitroglycerin in human veins. FASEB J 22: 2561-2568, 2008
140. Igamberdiev AU, Ratcliffe RG, and Gupta KJ. Plant mitochondria: source and target for nitric oxide. Mitochondrion 19 Pt B: 329-333, 2014
141. Ikejima H, Imanishi T, Tsujioka H, Kuroi A, Muragaki Y, Mochizuki S, Goto M, Yoshida K, and Akasaka T. Effect of pioglitazone on nitroglycerin-induced impairment of nitric oxide bioavailability by a catheter-type nitric oxide sensor. Circ J 72: 998-1002, 2008
142. Imai S, Ushijima T, Nakazawa M, Nabata H, and Sakai K. Mechanism of relaxant effects of nicorandil on the dog coronary artery. Arch Int Pharmacodyn Ther 265: 274-282, 1983
143. Ishikawa K, Kanamasa K, Ogawa I, Takenaka T, Naito T, Kamata N, Yamamoto T, Nakai S, Hama J, Oyaizu M, Kimura A, Yamamoto K, Aso N, Arai M, Yabushita H, and Katori Y. Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction. Secondary Prevention Group. Jpn Circ J 60: 779-788, 1996
144. Ishikawa K, Yamamoto T, Kanamasa K, Hayashi T, Takenaka T, Kimura A, Miyataka M, Yabushita H, Kitayama K; Secondary PreventionGroup. Intermittent nitrate therapy for priormyocardial infaraction does not induce rebound angina nor reduce cardiac events. Intern Med 39: 1020-1026, 2000
145. Jabs A, Oelze M, Mikhed Y, Stamm P, Kroller-Schon S, Welschof P, Jansen T, Hausding M, Kopp M, Steven S, Schulz E, Stasch JP, Munzel T, and Daiber A. Effect of soluble guanylyl cyclase activator and stimulator therapy on nitroglycerin-induced nitrate tolerance in rats. Vascul Pharmacol 71: 181-191, 2015
146. Jakschik B and Needleman P. Sulfhydryl reactivity of organic nitrates: biochemical basis for inhibition of glyceraldehyde-P dehydrogenase and monoamine oxidase. Biochem Biophys Res Commun 53: 539-544, 1973
147. Janero DR, Bryan NS, Saijo F, Dhawan V, Schwalb DJ, Warren MC, and Feelisch M. Differential nitros(yl)ation of blood and tissue constituents during glyceryl trinitrate biotransformation in vivo. Proc Natl Acad Sci U S A 101: 16958-16963, 2004
148. Jansson EA, Huang L, Malkey R, Govoni M, Nihlen C, Olsson A, Stensdotter M, Petersson J, Holm L, Weitzberg E, and Lundberg JO. A mammalian functional nitrate reductase that regulates nitrite and nitric oxide homeostasis. Nat Chem Biol 4: 411-417, 2008
149. Ji Y and Bennett BM. Biotransformation of glyceryl trinitrate by rat hepatic microsomal glutathione S-transferase 1. J Pharmacol Exp Ther 318: 1050-1056, 2006
150. Jurt U, Gori T, Ravandi A, Babaei S, Zeman P, and Parker JD. Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: a human in vivo study. J Am Coll Cardiol 38: 854-859, 2001
151. Kahler J, Ewert A, Weckmuller J, Stobbe S, Mittmann C, Koster R, Paul M, Meinertz T, and Munzel T. Oxidative stress increases endothelin-1 synthesis in human coronary artery smooth muscle cells. J Cardiovasc Pharmacol 38: 49-57, 2001
152. Kahler J, Mendel S, Weckmuller J, Orzechowski HD, Mittmann C, Koster R, Paul M, Meinertz T, and Munzel T. Oxidative stress increases synthesis of big endothelin-1by activation of the endothelin-1 promoter. J Mol Cell Cardiol 32: 1429-1437, 2000
153. KanamasaK, HayashiT,KimuraA, Ikeda A, and IshikawaK. Long-term, continuous treatment with both oral and transdermal nitrates increases cardiac events in healed myocardial infarction patients. Angiology 53: 399-408, 2002
154. Keaney JF Jr. Immune modulation of atherosclerosis. Circulation 124: e559-e560, 2011
155. Kessler P, Bauersachs J, Busse R, and Schini-Kerth VB. Inhibition of inducible nitric oxide synthase restores endothelium-dependent relaxations in proinflammatory mediator-induced blood vessels. Arterioscler Thromb Vasc Biol 17: 1746-1755, 1997
156. Kim D, Rybalkin SD, Pi X, Wang Y, Zhang C, Munzel T, Beavo JA, Berk BC, and Yan C. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance.Circulation 104: 2338-2343, 2001
157. Kimura S, Zhang GX, Nishiyama A, Shokoji T, Yao L, Fan YY, Rahman M, and Abe Y. Mitochondria-derived reactive oxygen species and vascular MAP kinases: comparison of angiotensin II and diazoxide. Hypertension 45: 438-444, 2005
158. Kleschyov AL, Oelze M, Daiber A, Huang Y, Mollnau H, Schulz E, Sydow K, Fichtlscherer B, Mulsch A, and Munzel T. Does nitric oxide mediate the vasodilator activity of nitroglycerin?. Circ Res 93: e104-e112, 2003
159. Knorr M, Hausding M, Kroller-Schuhmacher S, Steven S, Oelze M, Heeren T, Scholz A, Gori T, Wenzel P, Schulz E, Daiber A, and Munzel T. Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-Glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan. Arterioscler Thromb Vasc Biol 31: 2223-2231, 2011
160. Knorr M, Hausding M, Pfeffer A, Jurk K, Jansen T, Schwierczek K, Oelze M, Kroller-Schon S, Schulz E, Wenzel P, Gori T, Burgin K, Sartor D, Scherhag A, Munzel T, and Daiber A. In vitro and in vivo characterization of a new organic nitrate hybrid drug covalently bound to pioglitazone. Pharmacology 93: 203-215, 2014
161. Knorr M, Hausding M, Schulz E, Oelze M, Rummler R, Schuff A, Daub S, Schreiner J, Kroller-Schon S, Wenzel P, Gori T, Burgin K, Sartor D, Scherhag A, Munzel T, and Daiber A. Characterization of new organic nitrate hybrid drugs covalently bound to valsartan and cilostazol. Pharmacology 90: 193-204, 2012
162. Ko ML, Shi L, Huang CC, Grushin K, Park SY, and Ko GY. Circadian phase-dependent effect of nitric oxide on L-type voltage-gated calcium channels in avian cone photoreceptors. J Neurochem 127: 314-328, 2013
163. Koda K, Salazar-Rodriguez M, Corti F, Chan NY, Estephan R, Silver RB, Mochly-Rosen D, and Levi R. Aldehyde dehydrogenase activation prevents reperfusion arrhythmias by inhibiting local renin release from cardiac mast cells. Circulation 122: 771-781, 2010
164. Koenig A, Lange K, Konter J, Daiber A, Stalleicken D, Glusa E, and Lehmann J. Potency and in vitro tolerance of organic nitrates: partially denitrated metabolites contribute to the tolerance-devoid activity of pentaerythrityl tetranitrate. J Cardiovasc Pharmacol 50: 68-74, 2007
165. Kojda G, Stein D, Kottenberg E, Schnaith EM, and Noack E. In vivo effects of pentaerythrityl-tetranitrate and isosorbide-5-mononitrate on the development of atherosclerosis and endothelial dysfunction in cholesterol-fed rabbits. J Cardiovasc Pharmacol 25: 763-773, 1995
166. Kollau A, Beretta M, Gorren AC, Russwurm M, Koesling D, Schmidt K, and Mayer B. Bioactivation of nitroglycerin by ascorbate. Mol Pharmacol 72: 191-196, 2007
167. Kollau A, Beretta M, Russwurm M, Koesling D, Keung WM, Schmidt K, and Mayer B. Mitochondrial nitrite reduction coupled to soluble guanylate cyclase activation: lack of evidence for a role in the bioactivation of nitroglycerin. Nitric Oxide 20: 53-60, 2009
168. Kollau A, Hofer A, Russwurm M, Koesling D, Keung WM, Schmidt K, Brunner F, and Mayer B. Contribution of aldehyde dehydrogenase to mitochondrial bioactivation of nitroglycerin. Evidence for activation of purified soluble guanylyl cyclase via direct formation of nitric oxide. Biochem J 385: 769-777, 2005
169. Konter J, Mollmann U, and Lehmann J. NO-donors. Part 17: synthesis and antimicrobial activity of novel ketoconazole-NO-donor hybrid compounds. Bioorg Med Chem 16: 8294-8300, 2008
170. Kroller-Schon S, Steven S, Kossmann S, Scholz A, Daub S, Oelze M, Xia N, Hausding M, Mikhed Y, Zinssius E, Mader M, Stamm P, Treiber N, Scharffetter-Kochanek K, Li H, Schulz E, Wenzel P, Munzel T, and Daiber A. Molecular mechanisms of the crosstalk between mitochondria and NADPH oxidase through reactive oxygen species-studies in white blood cells and in animal models. Antioxid Redox Signal 20: 247-266, 2014
171. Kumar V, Martin F, Hahn MG, Schaefer M, Stamler JS, Stasch JP, and Van den Akker F. Insights into BAY 60-2770 activation and S-nitrosylation-dependent desensitization of soluble guanylyl cyclase via crystal structures of homologous nostoc H-NOX domain complexes. Biochemistry 52: 3601-3608, 2013
172. Kurz S,HinkU,NickenigG,BorthayreAB,HarrisonDG, and Munzel T. Evidence for a causal role of the renin-angiotensin system in nitrate tolerance. Circulation 99: 3181-3187, 1999
173. Kuzkaya N, Weissmann N, Harrison DG, and Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J BiolChem278: 22546-22554, 2003
174. Laghi Pasini F, Capecchi PL, Acciavatti A, Petri S, De Lalla A, Cati G, Colafati M, and Di Perri T. Pharmacological preconditioning of ischaemia. Clin Hemorheol Microcirc 17: 73-84, 1997
175. Lagranha CJ, Deschamps A, Aponte A, Steenbergen C, and Murphy E. Sex differences in the phosphorylation of mitochondrial proteins result in reduced production of reactive oxygen species and cardioprotection in females. Circ Res 106: 1681-1691, 2010
176. Lang BS, Gorren AC, Oberdorfer G, Wenzl MV, Furdui CM, Poole LB, Mayer B, and Gruber K. Vascular bioactivation of nitroglycerin by aldehyde dehydrogenase-2: reaction intermediates revealed by crystallography and mass spectrometry. J Biol Chem 287: 38124-38134, 2012
177. Larson HN, Zhou J, Chen Z, Stamler JS, Weiner H, and Hurley TD. Structural and functional consequences of coenzyme binding to the inactive Asian variant of mitochondrial aldehyde dehydrogenase: Roles of residues 475 and 487. J Biol Chem 282: 12940-12950, 2007
178. Lau DT and Benet LZ. Nitroglycerin metabolism in subcellular fractions of rabbit liver. Dose dependency of glyceryl dinitrate formation and possible involvement of multiple isozymes of glutathione S-transferases. Drug Metab Dispos 18: 292-297, 1990
179. Lebuffe G, Schumacker PT, Shao ZH, Anderson T, Iwase H, and Vanden Hoek TL. ROS and NO trigger early preconditioning: relationship to mitochondrial KATP channel. Am J Physiol Heart Circ Physiol 284: H299-H308, 2003
180. Leesar MA, Stoddard MF, Dawn B, Jasti VG, Masden R, and Bolli R. Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation 103: 2935-2941, 2001
181. LevyWS,KatzRJ, andWassermanAG.Methionine restores the venodilative response to nitroglycerin after the development of tolerance. J Am Coll Cardiol 17: 474-479, 1991
182. Li H, Cui H, Liu X, and Zweier JL. Xanthine oxidase catalyzes anaerobic transformation of organic nitrates to nitric oxide and nitrosothiols: characterization of this mechanism and the link between organic nitrate and guanylyl cyclase activation. J Biol Chem 280: 16594-16600, 2005
183. Li H, Liu X, Cui H, Chen YR, Cardounel AJ, and Zweier JL. Characterization of the mechanism of cytochrome P450 reductase-cytochrome P450-mediated nitric oxide and nitrosothiol generation from organic nitrates. J Biol Chem 281: 12546-12554, 2006
184. Li Y, ZhangD, Jin W, Shao C, Yan P,Xu C, Sheng H, LiuY, Yu J, XieY, ZhaoY, LuD,NebertDW, HarrisonDC,Huang W, and Jin L. Mitochondrial aldehyde dehydrogenase-2 (ALDH2) Glu504Lys polymorphism contributes to the variation in efficacy of sublingual nitroglycerin. J Clin Invest 116: 506-511, 2006
185. Lin MI, Fulton D, Babbitt R, Fleming I, Busse R, Pritchard KA Jr., and Sessa WC. Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of L-arginine metabolism to efficient nitric oxide production. J Biol Chem 278: 44719-44726, 2003
186. Lin S, Page NA, Fung SM, and Fung HL. In vitro organic nitrate bioactivation to nitric oxide by recombinant aldehyde dehydrogenase 3A1. Nitric Oxide 35: 137-143, 2013
187. Lisi M, Oelze M, Dragoni S, Liuni A, Steven S, Luca MC, Stalleicken D, Munzel T, Laghi-Pasini F, Daiber A, Parker JD, and Gori T. Chronic protection against ischemia and reperfusion-induced endothelial dysfunction during therapy with different organic nitrates. Clin Res Cardiol 101: 453-459, 2012
188. Liu CQ, Leung FP, Lee VW, Lau CW, Yao X, Lu L, and Huang Y. Prevention of nitroglycerin tolerance in vitro by T0156, a selective phosphodiesterase type 5 inhibitor. Eur J Pharmacol 590: 250-254, 2008
189. Liuni A, LucaMC, Di Stolfo G, Uxa A,Mariani JA, Gori T, and Parker JD. Coadministration of atorvastatin prevents nitroglycerin-induced endothelial dysfunction and nitrate tolerance in healthy humans. J Am Coll Cardiol 57: 93-98, 2011
190. Loot AE, Schreiber JG, Fisslthaler B, and Fleming I. Angiotensin II impairs endothelial function via tyrosine phosphorylation of the endothelial nitric oxide synthase. J Exp Med 206: 2889-2896, 2009
191. Lopez GV, Blanco F, Hernandez P, Ferreira A, Piro OE, Batthyany C, Gonzalez M, Rubbo H, and Cerecetto H. Second generation of alpha-tocopherol analogs-nitric oxide donors: synthesis, physicochemical, and biological characterization. Bioorg Med Chem 15: 6262-6272, 2007
192. Lundberg JO, Feelisch M, Bjorne H, Jansson EA, and Weitzberg E. Cardioprotective effects of vegetables: is nitrate the answer?. Nitric Oxide 15: 359-362, 2006
193. Ma H, Guo R, Yu L, Zhang Y, and Ren J. Aldehyde dehydrogenase 2 (ALDH2) rescues myocardial ischaemia/reperfusion injury: role of autophagy paradox and toxic aldehyde. Eur Heart J 32: 1025-1038, 2011
194. Ma H, Li J, Gao F, and Ren J. Aldehyde dehydrogenase 2 ameliorates acute cardiac toxicity of ethanol: role of protein phosphatase and forkhead transcription factor. J Am Coll Cardiol 54: 2187-2196, 2009
195. Mackenzie IS, Maki-Petaja KM, McEniery CM, Bao YP, Wallace SM, Cheriyan J, Monteith S, Brown MJ, and Wilkinson IB. Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans. Arterioscler Thromb Vasc Biol 25: 1891-1895, 2005
196. MacPherson JD, Gillespie TD, Dunkerley HA, Maurice DH, and Bennett BM. Inhibition of phosphodiesterase 5 selectively reverses nitrate tolerance in the venous circulation. J Pharmacol Exp Ther 317: 188-195, 2006
197. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2013 ESH/ESC practice guidelines for themanagement of arterial hypertension. Blood Press 23: 3-16, 2014
198. Martelli A, Rapposelli S, and Calderone V. NO-releasing hybrids of cardiovascular drugs. Curr Med Chem 13: 609-625, 2006
199. Mayer B, Kleschyov AL, Stessel H, Russwurm M, Munzel T, Koesling D, and Schmidt K. Inactivation of soluble guanylate cyclase by stoichiometric S-nitrosation. Mol Pharmacol 75: 886-891, 2009
200. McDonald BJ and Bennett BM. Cytochrome P-450 mediated biotransformation of organic nitrates. Can J Physiol Pharmacol 68: 1552-1557, 1990
201. McGrath LT, Dixon L, Morgan DR, and McVeigh GE. Production of 8-epi prostaglandin F(2alpha) in human platelets during administration of organic nitrates. J Am Coll Cardiol 40: 820-825, 2002
202. McManus DD, Beaulieu LM, Mick E, Tanriverdi K, Larson MG, Keaney JF Jr., Benjamin EJ, and Freedman JE. Relationship among circulating inflammatory proteins, platelet gene expression, and cardiovascular risk. Arterioscler Thromb Vasc Biol 33: 2666-2673, 2013
203. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, ZeiherA; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, SechtemU, Sirnes PA, TenderaM, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B,Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: theTask Force for the Diagnosis and Treatment ofAcute andChronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14: 803-869, 2012
204. McVeigh GE, Hamilton P, Wilson M, Hanratty CG, Leahey WJ, Devine AB, Morgan DG, Dixon LJ, and McGrath LT. Platelet nitric oxide and superoxide release during the development of nitrate tolerance: effect of supplemental ascorbate. Circulation 106: 208-213, 2002
205. Mehra A, Ostrzega E, Shotan A, Johnson JV, and Elkayam U. Persistent hemodynamic improvement with short-term nitrate therapy in patients with chronic congestive heart failure already treated with captopril. Am J Cardiol 70: 1310-1314, 1992
206. Milone SD, Azevedo ER, Forster C, and Parker JD. The angiotensin II-receptor antagonist losartan does not prevent hemodynamic or vascular tolerance to nitroglycerin. J Cardiovasc Pharmacol 34: 645-650, 1999
207. Milone SD, Pace-Asciak CR, Reynaud D, Azevedo ER, Newton GE, and Parker JD. Biochemical, hemodynamic, and vascular evidence concerning the free radical hypothesis of nitrate tolerance. J Cardiovasc Pharmacol 33: 685-690, 1999
208. Minamiyama Y, Takemura S, Akiyama T, Imaoka S, Inoue M, Funae Y, and Okada S. Isoforms of cytochrome P450 on organic nitrate-derived nitric oxide release in human heart vessels. FEBS Lett 452: 165-169, 1999
209. Minamiyama Y, Takemura S, Nishino Y, and Okada S. Organic nitrate tolerance is induced by degradation of some cytochrome P450 isoforms. Redox Rep 7: 339-342, 2002
210. Minamiyama Y, Takemura S, Yamasaki K, Hai S, Hirohashi K, Funae Y, and Okada S. Continuous administration of organic nitrate decreases hepatic cytochrome P450. J Pharmacol Exp Ther 308: 729-735, 2004
211. Minamiyama Y, Takemura S, Yamasaki K, Hai S, Hirohashi K, and Okada S. Continuous treatment with organic nitrate affects hepatic cytochrome P450. Redox Rep 9: 360-364, 2004
212. Molina CR, Andresen JW, Rapoport RM, Waldman S, and Murad F. Effect of in vivo nitroglycerin therapy on endothelium-dependent and independent vascular relaxation and cyclic GMP accumulation in rat aorta. J Cardiovasc Pharmacol 10: 371-378, 1987
213. Molina y Vedia L, McDonald B, Reep B, Brune B, Di Silvio M, Billiar TR, and Lapetina EG. Nitric oxide-induced Snitrosylation of glyceraldehyde-3-phosphate dehydrogenase inhibits enzymatic activity and increases endogenous ADPribosylation. J Biol Chem 267: 24929-24932, 1992
214. Mollace V, Muscoli C, Dagostino C, Giancotti LA, Gliozzi M, Sacco I, Visalli V, Gratteri S, Palma E, Malara N, Musolino V, Carresi C, Muscoli S, Vitale C, Salvemini D, and Romeo F. The effect of peroxynitrite decomposition catalyst MnTBAP on aldehyde dehydrogenase-2 nitration by organic nitrates: role in nitrate tolerance. Pharmacol Res 89: 29-35, 2014
215. MoonKH,KimBJ, and Song BJ. Inhibition ofmitochondrial aldehyde dehydrogenase by nitric oxide-mediated Snitrosylation. FEBS Lett 579: 6115-6120, 2005
216. Morawietz H. Endothelial NADPH oxidases: friends or foes?. Basic Res Cardiol 106: 521-525, 2011
217. Morelli A, Filippi S, Vignozzi L, Mancina R, and Maggi M. Physiology of erectile function: an update on intracellular molecular processes. EAU-EBU Update Ser 4: 96-108, 2006
218. Mulsch A, Bara A, Mordvintcev P, Vanin A, and Busse R. Specificity of different organic nitrates to elicit NO formation in rabbit vascular tissues and organs in vivo. Br J Pharmacol 116: 2743-2749, 1995
219. Mulsch A, Busse R, and Bassenge E. Desensitization of guanylate cyclase in nitrate tolerance does not impair endothelium-dependent responses. Eur J Pharmacol 158: 191-198, 1988
220. Mulsch A, Oelze M, Kloss S, Mollnau H, Topfer A, Smolenski A, Walter U, Stasch JP, Warnholtz A, Hink U, Meinertz T, and Munzel T. Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta. Circulation 103: 2188-2194, 2001
221. Munzel T, Daiber A, and Gori T. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation 123: 2132-2144, 2011
222. Munzel T, Daiber A, and Gori T. More answers to the still unresolved question of nitrate tolerance. Eur Heart J 34: 2666-2673, 2013
223. Munzel T, Daiber A, and Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res 97: 618-628, 2005
224. Munzel T, Daiber A, Ullrich V, and Mulsch A. Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscler Thromb Vasc Biol 25: 1551-1557, 2005
225. Munzel T, Feil R, Mulsch A, Lohmann SM, Hofmann F, and Walter U. Physiology and pathophysiology of vascular signaling controlled by guanosine 3¢,5¢-cyclic monophosphate-dependent protein kinase [corrected]. Circulation 108: 2172-2183, 2003
226. Munzel T, Giaid A, Kurz S, Stewart DJ, and Harrison DG. Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci U S A 92: 5244-5248, 1995
227. Munzel T, Gori T, Bruno RM, and Taddei S. Is oxidative stress a therapeutic target in cardiovascular disease?. Eur Heart J 31: 2741-2748, 2010
228. Munzel T, Heitzer T, Kurz S, Harrison DG, Luhman C, Pape L, Olschewski M, and Just H. Dissociation of coronary vascular tolerance and neurohormonal adjustments during long-term nitroglycerin therapy in patients with stable coronary artery disease. J Am Coll Cardiol 27: 297-303, 1996
229. Munzel T, Holtz J, Mulsch A, Stewart DJ, and Bassenge E. Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetylcysteine in vivo, but tolerance-independent interactions exist. Circulation 79: 188-197, 1989
230. Munzel T, Kurz S, Rajagopalan S, Tarpey M, Freeman B, and Harrison DG. Identification of the membrane bound NADH oxidase as the major source of superoxide anion in nitrate tolerance. Endothelium 3 Suppl: s14 (abstract), 1995
231. Munzel T, Kurz S, Rajagopalan S, Thoenes M, Berrington WR, Thompson JA, Freeman BA, and Harrison DG. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest 98: 1465-1470, 1996
232. Munzel T, Li H, Mollnau H, Hink U, Matheis E, Hartmann M, Oelze M, Skatchkov M, Warnholtz A, Duncker L, Meinertz T, and Forstermann U. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Circ Res 86: E7-E12, 2000
233. Munzel T, Meinertz T, Tebbe U, Schneider HT, Stalleicken D, Wargenau M, Gori T, Klingmann I; Cleopatra Study Investigators. Efficacy of the long-acting nitro vasodilator pentaerithrityl tetranitrate in patients with chronic stable angina pectoris receiving anti-anginal background therapy with beta-blockers: a 12-week, randomized, double-blind, placebo-controlled trial. Eur Heart J 35: 895-903, 2014
234. Munzel T, Mollnau H, Hartmann M, Geiger C, Oelze M, Warnholtz A, Yehia AH, Forstermann U, and Meinertz T. Effects of a nitrate-free interval on tolerance, vasoconstrictor sensitivity and vascular superoxide production. J Am Coll Cardiol 36: 628-634, 2000
235. Munzel T, Mulsch A, Holtz J, Just H, Harrison DG, and Bassenge E. Mechanisms of interaction between the sulfhydryl precursor L-methionine and glyceryl trinitrate. Circulation 86: 995-1003, 1992
236. Munzel T, Sayegh H, Freeman BA, Tarpey MM, and Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 95: 187-194, 1995
237. Munzel T, Sinning C, Post F, Warnholtz A, and Schulz E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 40: 180-196, 2008
238. Munzel T, Steven S, and Daiber A. Organic nitrates: update on mechanisms underlying vasodilation, tolerance and endothelial dysfunction. Vascul Pharmacol 63: 105-113, 2014
239. Murry CE, Jennings RB, and Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136, 1986
240. Nakamura Y, Moss AJ, Brown MW, Kinoshita M, and Kawai C. Long-term nitrate use may be deleterious in ischemic heart disease: a study using the databases from two largescale postinfarction studies. Multicenter Myocardial Ischemia Research Group. Am Heart J 138: 577-585, 1999
241. Nazarewicz RR, Dikalova AE, Bikineyeva A, and Dikalov SI. Nox2 as a potential target of mitochondrial superoxide and its role in endothelial oxidative stress. Am J Physiol Heart Circ Physiol 305: H1131-H1140, 2013
242. Needleman P and Hunter FE Jr. Effects of organic nitrates on mitochondrial respiration and swelling: possible correlations with the mechanism of pharmacologic action. Mol Pharmacol 2: 134-143, 1966
243. Needleman P, Jakschik B, and Johnson EM Jr. Sulfhydryl requirement for relaxation of vascular smooth muscle. J Pharmacol Exp Ther 187: 324-331, 1973
244. Needleman P, and Johnson EM Jr. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther 184: 709-715, 1973
245. Neubauer R, Wolkart G, Opelt M, Schwarzenegger C, HofingerM, Neubauer A, Kollau A, Schmidt K, Schrammel A, and Mayer B. Aldehyde dehydrogenase-independent bioactivation of nitroglycerin in porcine and bovine blood vessels. Biochem Pharmacol 93: 440-448, 2015
246. Neurath GB and Dunger M. Blood levels of the metabolites of glyceryl trinitrate and pentaerythritol tetranitrate after administration of a two-step preparation. Arzneimittelforschung 27: 416-419, 1977
247. Nigam R,Whiting T, and Bennett BM. Effect of inhibitors of glutathione S-transferase on glyceryl trinitrate activity in isolated rat aorta. Can J Physiol Pharmacol 71: 179-184, 1993
248. Noack E and Feelisch M. Molecular mechanisms of nitrovasodilator bioactivation. Basic Res Cardiol 86 Suppl 2: 37-50, 1991
249. Nunez C, Victor VM, Tur R, Alvarez-Barrientos A, Moncada S, Esplugues JV, and D'Ocon P. Discrepancies between nitroglycerin and NO-releasing drugs on mitochondrial oxygen consumption, vasoactivity, and the release of NO. Circ Res 97: 1063-1069, 2005
250. Oberle S, Abate A, Grosser N, Hemmerle A, Vreman HJ, Dennery PA, Schneider HT, Stalleicken D, and Schroder H. Endothelial protection by pentaerithrityl trinitrate: bilirubin and carbon monoxide as possible mediators. Exp Biol Med (Maywood) 228: 529-534, 2003
251. Oberle S, Abate A, Grosser N, Vreman HJ, Dennery PA, Schneider HT, Stalleicken D, and Schroder H. Heme oxygenase-1 induction may explain the antioxidant profile of pentaerythrityl trinitrate. Biochem Biophys Res Commun 290: 1539-1544, 2002
252. Oberle S, Schwartz P, Abate A, and Schroder H. The antioxidant defense protein ferritin is a novel and specific target for pentaerithrityl tetranitrate in endothelial cells. Biochem Biophys Res Commun 261: 28-34, 1999
253. Oelze M, Knorr M, Kroller-Schon S, Kossmann S, GottschlichA, RummlerR, Schuff A, Daub S,DopplerC,Kleinert H, Gori T, Daiber A, and Munzel T. Chronic therapy with isosorbide-5-mononitrate causes endothelial dysfunction, oxidative stress, and a marked increase in vascular endothelin-1 expression. Eur Heart J 34: 3206-3216, 2013
254. Oelze M, Knorr M, Schell R, Kamuf J, Pautz A, Art J, Wenzel P, Munzel T, Kleinert H, and Daiber A. Regulation of humanmitochondrial aldehyde dehydrogenase (ALDH-2) activity by electrophiles in vitro. J Biol Chem 286: 8893-8900, 2011
255. Oelze M, Kroller-Schon S, Steven S, Lubos E, Doppler C, Hausding M, Tobias S, Brochhausen C, Li H, Torzewski M, Wenzel P, BachschmidM, Lackner KJ, Schulz E, Munzel T, and Daiber A. Glutathione peroxidase-1 deficiency potentiates dysregulatory modifications of endothelial nitric oxide synthase and vascular dysfunction in aging. Hypertension 63: 390-396, 2014
256. Oppermann M, Balz V, Adams V, Dao VT, Bas M, Suvorava T, and Kojda G. Pharmacological induction of vascular extracellular superoxide dismutase expression in vivo. J Cell Mol Med 13: 1271-1278, 2009
257. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, and Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 317: 799-804, 1987
258. Pagani ED, VanAller GS, O'Connor B, and Silver PJ. Reversal of nitroglycerin tolerance in vitro by the cGMPphosphodiesterase inhibitor zaprinast. Eur J Pharmacol 243: 141-147, 1993
259. Parker JD. Potential problems with intermittent nitrate therapy. Can J Cardiol 12 Suppl C: 22C-24C, 1996
260. Parker JD, Farrell B, Fenton T, Cohanim M, and Parker JO. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation 84: 2336-2345, 1991
261. Parker JD, Parker AB, Farrell B, and Parker JO. Intermittent transdermal nitroglycerin therapy. Decreased anginal threshold during the nitrate-free interval. Circulation 91: 973-978, 1995
262. Parker JD and Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med 338: 520-531, 1998
263. Pasch T, Kleierl-Lindner C, Gotz H, and Pichl J. [Rebound hypertension after controlled hypotension and its prevention by captopril]. Anaesthesist 35: 66-72, 1986
264. Pautz A, Rauschkolb P, Schmidt N, Art J, Oelze M, Wenzel P, Forstermann U, Daiber A, and Kleinert H. Effects of nitroglycerin or pentaerithrityl tetranitrate treatment on the gene expression in rat hearts: evidence for cardiotoxic and cardioprotective effects. Physiol Genomics 38: 176-185, 2009
265. Pepine CJ, Lopez LM, Bell DM, Handberg-Thurmond EM, Marks RG, and McGorray S. Effects of intermittent transdermal nitroglycerin on occurrence of ischemia after patch removal: results of the second transdermal intermittent dosing evaluation study (TIDES-II). J Am Coll Cardiol 30: 955-961, 1997
266. Rezkalla SH and Kloner RA. Preconditioning in humans. Heart Fail Rev 12: 201-206, 2007
267. Riego JA, Broniowska KA, Kettenhofen NJ, and Hogg N. Activation and inhibition of soluble guanylyl cyclase by S-nitrosocysteine: involvement of amino acid transport system L. Free Radic Biol Med 47: 269-274, 2009
268. Sage PR, De la Lande IS, Stafford I, Bennett CL, Phillipov G, Stubberfield J, and Horowitz JD. Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation 102: 2810-2815, 2000
269. Sakuma K, Fukuda S, Fujiwara N, Tsukui A, Tanaka T, and Shimoji K. Vasorelaxation by nitroglycerin of the isolated porcine coronary artery during hypoxia. Jpn J Pharmacol 58 Suppl 2: 319P, 1992
270. Sayed N, Baskaran P, Ma X, Van den Akker F, and Beuve A. Desensitization of soluble guanylyl cyclase, the NO receptor, by S-nitrosylation. Proc Natl Acad Sci U S A 104: 12312-12317, 2007
271. Sayed N, Kim DD, Fioramonti X, Iwahashi T, Duran WN, and Beuve A. Nitroglycerin-induced S-nitrosylation and desensitization of soluble guanylyl cyclase contribute to nitrate tolerance. Circ Res 103: 606-614, 2008
272. Schmidt K, Neubauer A, Kolesnik B, Stasch JP, Werner ER, Gorren AC, and Mayer B. Tetrahydrobiopterin protects soluble guanylate cyclase against oxidative inactivation.Mol Pharmacol 82: 420-427, 2012
273. Schmidt K, Rehn M, Stessel H, Wolkart G, and Mayer B. Evidence against tetrahydrobiopterin depletion of vascular tissue exposed to nitric oxide/superoxide or nitroglycerin. Free Radic Biol Med 48: 145-152, 2010
274. Schmidt P, Youhnovski N, Daiber A, Balan A, Arsic M, Bachschmid M, Przybylski M, and Ullrich V. Specific nitration at tyrosine 430 revealed by high resolution mass spectrometry as basis for redox regulation of bovine prostacyclin synthase. J Biol Chem 278: 12813-12819, 2003
275. Schnorbus B, Schiewe R, Ostad MA, Medler C, Wachtlin D, Wenzel P, Daiber A, Munzel T, and Warnholtz A. Effects of pentaerythritol tetranitrate on endothelial function in coronary artery disease: results of the PENTA study. Clin Res Cardiol 99: 115-124, 2010
276. Schroder H. Cytochrome P-450 mediates bioactivation of organic nitrates. J Pharmacol Exp Ther 262: 298-302, 1992
277. Schroder H, Noack E, and Muller R. Evidence for a correlation between nitric oxide formation by cleavage of organic nitrates and activation of guanylate cyclase. J Mol Cell Cardiol 17: 931-934, 1985
278. Schuhmacher S, Oelze M, Bollmann F, Kleinert H, Otto C, Heeren T, Steven S, Hausding M, Knorr M, Pautz A, Reifenberg K, Schulz E, Gori T, Wenzel P, Munzel T, and Daiber A. Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy. Diabetes 60: 2608-2616, 2011
279. Schuhmacher S, Wenzel P, Schulz E, Oelze M, Mang C, Kamuf J, Gori T, Jansen T, Knorr M, Karbach S, Hortmann M,Mathner F,Bhatnagar A, ForstermannU,LiH,MunzelT, and Daiber A. Pentaerythritol tetranitrate improves angiotensin II-induced vascular dysfunction via induction of heme oxygenase-1. Hypertension 55: 897-904, 2010
280. Schulz E, Jansen T, Wenzel P, Daiber A, and Munzel T. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal 10: 1115-1126, 2008
281. Schulz E, TsilimingasN,Rinze R, Reiter B,WendtM,Oelze M, Woelken-Weckmuller S, Walter U, Reichenspurner H, Meinertz T, and Munzel T. Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vesselswith and without nitroglycerin pretreatment. Circulation 105: 1170-1175, 2002
282. Schulz E, Wenzel P, Munzel T, and Daiber A. Mitochondrial redox signaling: interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. Antioxid Redox Signal 20: 308-324, 2014
283. Schwartz AM. The cause, relief and prevention of headaches arising from contact with dynamite. N Engl J Med 235: 541-544, 1946
284. Seabra AB, Ouellet M, Antonic M, Chretien MN, and English AM. Catalysis of nitrite generation from nitroglycerin by glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Nitric Oxide 35: 116-122, 2013
285. SeelingAand Lehmann J.NO-donors, part X: investigations on the stability of pentaerythrityl tetranitrate (PETN) by HPLC-chemoluminescence-N-detection (CLND) versus UV-detection in HPLC. J Pharm Biomed Anal 40: 1131-1136, 2006
286. Sekiya M, Sato M, Funada J, Ohtani T, Akutsu H, and Watanabe K. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol 46: 63-67, 2005
287. Sellke FW,Myers PR, Bates JN, and Harrison DG. Influence of vessel size on the sensitivity of porcine coronary microvessels to nitroglycerin.AmJ Physiol 258: H515-H520, 1990
288. Sellke FW, Tomanek RJ, and Harrison DG. L-cysteine selectively potentiates nitroglycerin-induced dilation of small coronary microvessels. J Pharmacol Exp Ther 258: 365-369, 1991
289. Shen C,Wang C, Fan F, Yang Z, Cao Q, Liu X, Sun X, Zhao X, Wang P, Ma X, Zhu H,Dong Z, Zou Y, Hu K, Sun A, and Ge J. Acetaldehyde dehydrogenase 2 (ALDH2) deficiency exacerbates pressure overload-induced cardiac dysfunction by inhibiting Beclin-1 dependent autophagy pathway. Biochim Biophys Acta 1852: 310-318, 2015
290. Silver PJ, Pagani ED, De Garavilla L, Van Aller GS, Volberg ML, Pratt PF, and Buchholz RA. Reversal or nitroglycerin tolerance by the cGMP phosphodiesterase inhibitor zaprinast. Eur J Pharmacol 199: 141-142, 1991
291. Simon WC, Anderson DJ, and Bennett BM. Inhibition of the pharmacological actions of glyceryl trinitrate after the electroporetic delivery of a glutathione S-transferase inhibitor. J Pharmacol Exp Ther 279: 1535-1540, 1996
292. Sobrero A. Computes Rendus 24 (1847), 247-248
293. Sobrero A. La Nitroglycerina, La Nitromannite e La Cellulosa Nitrica. Acad Sci Torino V: 670-678, 1870
294. Song BJ, Abdelmegeed MA, Yoo SH, Kim BJ, Jo SA, Jo I, and Moon KH. Post-translational modifications of mitochondrial aldehyde dehydrogenase and biomedical implications. J Proteomics 74: 2691-2702, 2011
295. Souza JM and Radi R. Glyceraldehyde-3-phosphate dehydrogenase inactivation by peroxynitrite. Arch Biochem Biophys 360: 187-194, 1998
296. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schroder H, Stahl E, Steinke W, and Wunder F. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 136: 773-783, 2002
297. Stewart DD. Remarkable tolerance to nitroglycerin. Phila Polyclinic 6: 43, 1888
298. Stewart DJ, Elsner D, Sommer O, Holtz J, and Bassenge E. Altered spectrum of nitroglycerin action in long-term treatment: nitroglycerin-specific venous tolerance with maintenance of arterial vasodepressor potency. Circulation 74: 573-582, 1986
299. Stewart DJ, Holtz J, and Bassenge E. Long-term nitroglycerin treatment: effect on direct and endotheliummediated large coronary artery dilation in conscious dogs. Circulation 75: 847-856, 1987
300. Sugamura K and Keaney JF Jr. Reactive oxygen species in cardiovascular disease. Free Radic Biol Med 51: 978-992, 2011
301. Sun A, Zou Y, Wang P, Xu D, Gong H, Wang S, Qin Y, Zhang P, Chen Y, Harada M, Isse T, Kawamoto T, Fan H, Yang P, Akazawa H, Nagai T, Takano H, Ping P, Komuro I, and Ge J. Mitochondrial aldehyde dehydrogenase 2 plays protective roles in heart failure after myocardial infarction via suppression of the cytosolic JNK/p53 pathway in mice. J Am Heart Assoc 3: e000779, 2014
302. Sun JX, PirainoAJ,Morgan JM, Joshi JC,CiprianoA,ChanK, and Redalieu E. Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable-isotope technique. JClinPharmacol 35: 390-397, 1995
303. Sun L, Ferreira JC, and Mochly-Rosen D. ALDH2 activator inhibits increased myocardial infarction injury by nitroglycerin tolerance. Sci Transl Med 3: 107ra111, 2011
304. Sydow K, Daiber A, OelzeM, Chen Z, AugustM,Wendt M, UllrichV,MulschA, Schulz E,Keaney JF Jr., Stamler JS, and Munzel T. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest 113: 482-489, 2004
305. Sydow K and Munzel T. ADMA and oxidative stress. Atheroscler Suppl 4: 41-51, 2003
306. Szocs K, Lassegue B, Wenzel P, Wendt M, Daiber A, Oelze M, Meinertz T, Munzel T, and Baldus S. Increased superoxide production in nitrate tolerance is associated with NAD(P)H oxidase and aldehyde dehydrogenase 2 downregulation. J Mol Cell Cardiol 42: 1111-1118, 2007
307. Takac I, Schroder K, and Brandes RP. The Nox family of NADPH oxidases: friend or foe of the vascular system?. Curr Hypertens Rep 14: 70-78, 2012
308. Takahashi J,Nihei T, Takagi Y,Miyata S,OdakaY,Tsunoda R, Seki A, Sumiyoshi T,MatsuiM,Goto T, TanabeY, Sueda S, Momomura S, Yasuda S, Ogawa H, Shimokawa H; Japanese Coronary Spasm Association. Prognostic impact of chronic nitrate therapy in patients with vasospastic angina: multicentre registry study of the Japanese coronary spasm association. Eur Heart J 36: 228-237, 2015
309. Tamano S, Ward JM, Diwan BA, Keefer LK, Weghorst CM, Calvert RJ, Henneman JR, Ramljak D, and Rice JM. Histogenesis and the role of p53 and K-ras mutations in hepatocarcinogenesis by glyceryl trinitrate (nitroglycerin) in male F344 rats. Carcinogenesis 17: 2477-2486, 1996
310. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F,ArdenC, BudajA,BugiardiniR,Crea F, Cuisset T,DiMario C, Ferreira JR, Gersh BJ,Gitt AK, Hulot JS,Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, SabateM, SeniorR, TaggartDP, Van derWall EE,Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Ryden L, SimoonsML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, and Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34: 2949-3003, 2013
311. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr., Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, and Cohn JN. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351: 2049-2057, 2004
312. Thomas GR, DiFabio JM, Gori T, and Parker JD. Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a freeradical-mediated mechanism. J Am Coll Cardiol 49: 1289-1295, 2007
313. Thum T, Fraccarollo D, Thum S, Schultheiss M, Daiber A, Wenzel P, Munzel T, Ertl G, and Bauersachs J. Differential effects of organic nitrates on endothelial progenitor cells are determined by oxidative stress. Arterioscler Thromb Vasc Biol 27: 748-754, 2007
314. Torfgard KE and Ahlner J. Effect of low dose of dipyridamole on glyceryl trinitrate tolerance in healthy volunteers. J Cardiovasc Pharmacol 21: 516-521, 1993
315. Tsou PS, Page NA, Lee SG, Fung SM, KeungWM, and Fung HL. Differential metabolism of organic nitrates by aldehyde dehydrogenase 1a1 and 2: substrate selectivity, enzyme inactivation, and active cysteine sites. AAPS J 13: 548-555, 2011
316. Umbrello M, Dyson A, Pinto BB, Fernandez BO, Simon V, Feelisch M, and Singer M. Short-term hypoxic vasodilation in vivo is mediated by bioactive nitric oxide metabolites, rather than free nitric oxide derived from haemoglobinmediated nitrite reduction. J Physiol 592: 1061-1075, 2014
317. Wang J, Wang H, Hao P, Xue L, Wei S, Zhang Y, and Chen Y. Inhibition of aldehyde dehydrogenase 2 by oxidative stress is associated with cardiac dysfunction in diabetic rats. Mol Med 17: 172-179, 2011
318. Wang L, Yang Y, Dwivedi S, Xu Y, Chu ET, Li J, Fitchett K, and Boor PJ. Manipulating glutathione-S-transferases may prevent the development of tolerance to nitroglycerin. Cardiovasc Toxicol 6: 131-144, 2006
319. Warnholtz A, Mollnau H, Heitzer T, Kontush A, Moller-Bertram T, Lavall D, Giaid A, Beisiegel U, Marklund SL, Walter U, Meinertz T, and Munzel T. Adverse effects of nitroglycerin treatment on endothelial function, vascular nitrotyrosine levels and cGMP-dependent protein kinase activity in hyperlipidemic Watanabe rabbits. J Am Coll Cardiol 40: 1356-1363, 2002
320. Watanabe H, Kakihana M, Ohtsuka S, and Sugishita Y. Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. J AmCollCardiol 32: 1194-1200, 1998
321. Weber M, Lauer N, Mulsch A, and Kojda G. The effect of peroxynitrite on the catalytic activity of soluble guanylyl cyclase. Free Radic Biol Med 31: 1360-1367, 2001
322. Weber W, Michaelis K, Luckow V, Kuntze U, and Stalleicken D. Pharmacokinetics and bioavailability of pentaerithrityl tetranitrate and two of its metabolites. Arzneimittelforschung 45: 781-784, 1995
323. Wenzel P, Hink U, Oelze M, Schuppan S, Schaeuble K, Schildknecht S, Ho KK,Weiner H, BachschmidM, Munzel T, and Daiber A. Role of reduced lipoic acid in the redox regulation of mitochondrial aldehyde dehydrogenase (ALDH-2) activity. Implications formitochondrial oxidative stress and nitrate tolerance. J BiolChem282: 792-799, 2007
324. Wenzel P, Hink U, Oelze M, Seeling A, Isse T, Bruns K, Steinhoff L, Brandt M, Kleschyov AL, Schulz E, Lange K, Weiner H, Lehmann J, Lackner KJ, Kawamoto T, Munzel T, and Daiber A. Number of nitrate groups determines reactivity and potency of organic nitrates: a proof of concept study in ALDH-2-/- mice. Br J Pharmacol 150: 526-533, 2007
325. Wenzel P, Mollnau H, Oelze M, Schulz E, Wickramanayake JM, Muller J, Schuhmacher S, Hortmann M, Baldus S, Gori T, Brandes RP, Munzel T, and Daiber A. First evidence for a crosstalk between mitochondrial and NADPH oxidase-derived reactive oxygen species in nitroglycerintriggered vascular dysfunction. Antioxid Redox Signal 10: 1435-1447, 2008
326. Wenzel P, Muller J, Zurmeyer S, Schuhmacher S, Schulz E, Oelze M, Pautz A, Kawamoto T, Wojnowski L, Kleinert H, Munzel T, and Daiber A. ALDH-2 deficiency increases cardiovascular oxidative stress-evidence for indirect antioxidative properties. Biochem Biophys Res Commun 367: 137-143, 2008
327. Wenzel P, Oelze M, Coldewey M, Hortmann M, Seeling A, Hink U, Mollnau H, Stalleicken D, Weiner H, Lehmann J, Li H, Forstermann U, Munzel T, and Daiber A. Heme oxygenase-1: a novel key player in the development of tolerance in response to organic nitrates. Arterioscler Thromb Vasc Biol 27: 1729-1735, 2007
328. Wenzel P, Schuhmacher S, Kienhofer J, Muller J, Hortmann M, Oelze M, Schulz E, Treiber N, Kawamoto T, Scharffetter-Kochanek K, Munzel T, Burkle A, Bachschmid MM, and Daiber A. Manganese superoxide dismutase and aldehyde dehydrogenase deficiency increase mitochondrial oxidative stress and aggravate age-dependent vascular dysfunction. Cardiovasc Res 80: 280-289, 2008
329. This reference has been deleted
330. Wenzel P, Schulz E, Gori T, Ostad MA, Mathner F, Schildknecht S, Gobel S, Oelze M, StalleickenD,Warnholtz A, Munzel T, and Daiber A. Monitoring white blood cell mitochondrial aldehyde dehydrogenase activity: implications for nitrate therapy in humans. J Pharmacol Exp Ther 330: 63-71, 2009
331. Wenzl MV, Beretta M, Gorren AC, Zeller A, Baral PK, Gruber K, Russwurm M, Koesling D, Schmidt K, and Mayer B. Role of the general base Glu-268 in nitroglycerin bioactivation and superoxide formation by aldehyde dehydrogenase-2. J Biol Chem 284: 19878-19886, 2009
332. Wenzl MV, Wolkart G, Stessel H, Beretta M, Schmidt K, and Mayer B. Different effects of ascorbate deprivation and classical vascular nitrate tolerance on aldehyde dehydrogenase-catalysed bioactivation of nitroglycerin. Br J Pharmacol 156: 1248-1255, 2009
333. Wey MC, Fernandez E, Martinez PA, Sullivan P, Goldstein DS, and Strong R. Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease. PLoS One 7: e31522, 2012
334. Wingler K, Hermans JJ, Schiffers P, Moens A, Paul M, and Schmidt HH. NOX1, 2, 4, 5: counting out oxidative stress. Br J Pharmacol 164: 866-883, 2011
335. Wolkart G, Beretta M, Wenzl MV, Stessel H, Schmidt K, Maeda N, Mayer B, and Schrammel A. Tolerance to nitroglycerin through proteasomal down-regulation of aldehyde dehydrogenase-2 in a genetic mouse model of ascorbate deficiency. Br J Pharmacol 168: 1868-1877, 2013
336. Wolkart G, Wenzl MV, Beretta M, Stessel H, Schmidt K, and Mayer B. Vascular tolerance to nitroglycerin in ascorbate deficiency. Cardiovasc Res 79: 304-312, 2008
337. Woodward AJ, Lewis PA, Rudman AR, and Maddock J. Determination of nitroglycerin and its dinitrate metabolites in human plasma by high-performance liquid chromatography with thermal energy analyzer detection. J Pharm Sci 73: 1838-1840, 1984
338. Wu F, Szczepaniak WS, Shiva S, Liu H, Wang Y, Wang L, Wang Y, Kelley EE, Chen AF, Gladwin MT, and McVerry BJ. Nox2-dependent glutathionylation of endothelial NOS leads to uncoupled superoxide production and endothelial barrier dysfunction in acute lung injury. Am J Physiol Lung Cell Mol Physiol 307: L987-L997, 2014
339. Wu Z, Siuda D, Xia N, Reifenberg G, Daiber A, Munzel T, Forstermann U, and Li H. Maternal treatment of spontaneously hypertensive rats with pentaerythritol tetranitrate reduces blood pressure in female offspring. Hypertension 65: 232-237, 2015
340. Xiao Q, Weiner H, and Crabb DW. The mutation in the mitochondrial aldehyde dehydrogenase (ALDH2) gene responsible for alcohol-induced flushing increases turnover of the enzyme tetramers in a dominant fashion. J Clin Invest 98: 2027-2032, 1996
341. Xu J, Wang S, Wu Y, Song P, and Zou MH. Tyrosine nitration of PA700 activates the 26S proteasome to induce endothelial dysfunction in mice with angiotensin IIinduced hypertension. Hypertension 54: 625-632, 2009
342. Xu J, Wu Y, Song P, Zhang M, Wang S, and Zou MH. Proteasome-dependent degradation of guanosine 5¢-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetes mellitus. Circulation 116: 944-953, 2007
343. Yada T, Shimokawa H, and Kajiya F. Cardioprotective effect of hydroxyfasudil as a specific Rho-kinase inhibitor, on ischemia-reperfusion injury in canine coronary microvessels in vivo. Clin Hemorheol Microcirc 34: 177-183, 2006
344. Yao L, Fan P, Arolfo M, Jiang Z, Olive MF, Zablocki J, Sun HL, Chu N, Lee J, Kim HY, Leung K, Shryock J, Blackburn B, and Diamond I. Inhibition of aldehyde dehydrogenase-2 suppresses cocaine seeking by generating THP, a cocaine use-dependent inhibitor of dopamine synthesis. Nat Med 16: 1024-1028, 2010
345. Yiu KH, Pong V, Siu CW, Lau CP, and Tse HF. Longterm oral nitrate therapy is associated with adverse outcome in diabetic patients following elective percutaneous coronary intervention. Cardiovasc Diabetol 10: 52, 2011
346. Zhang GG, Shi RZ, Jiang DJ, Chen YR, Jia C, Tang ZY, Bai YP, Xiao HB, and Li YJ. Involvement of the endothelial DDAH/ADMA pathway in nitroglycerin tolerance: the role of ALDH-2. Life Sci 82: 699-707, 2008
347. Zhang J, Chen Z, Cobb FR, and Stamler JS. Role of mitochondrial aldehyde dehydrogenase in nitroglycerininduced vasodilation of coronary and systemic vessels: an intact canine model. Circulation 110: 750-755, 2004
348. Zhang XJ, Chang L, Zhang YM, Deng S, Li YJ, and Peng J. Comparing the role of glutathione-S-transferase and mitochondrial aldehyde dehydrogenase in nitroglycerin biotransformation and the correlation with calcitonin gene-related peptide. Eur J Pharmacol 617: 97-101, 2009
349. Zobel LR, Finkelstein SM, Carlyle PF, and Cohn JN. Pressure pulse contour analysis in determining the effect of vasodilator drugs on vascular hemodynamic impedance characteristics in dogs. Am Heart J 100: 81-88, 1980
350. Zou MH and Bachschmid M. Hypoxia-reoxygenation triggers coronary vasospasm in isolated bovine coronary arteries via tyrosine nitration of prostacyclin synthase. J Exp Med 190: 135-139, 1999
351. ZouMH, ShiC, andCohenRA.Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 109: 817-826, 2002